Vera Therapeutics reports FY2022 net loss $89.1M; positive atacicept interim data; plans Phase 3 in Q2 2023

Vera Therapeutics, Inc.

Positive interim Phase 2b ORIGIN data: 41% mean proteinuria reduction vs baseline at 24 weeks in 150mg dose.
36-week data on track for Q2 2023; Phase 3 initiation planned for Q2 2023.
FY2022 net loss $89.1M ($3.35/share) vs $32.6M ($2.43) prior year.
Cash $114.7M as of Dec 31, 2022; raised ~$107.6M net in Feb 2023 offering.
Prioritizing atacicept for IgAN; funds expected to last to early 2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Vera Therapeutics, Inc. reported the full year ended December 31, 2022 results: net income net loss of $89.1 million, EPS a net loss per diluted share of $3.35.

Period: the full year ended December 31, 2022
Net income: net loss of $89.1 million
EPS: a net loss per diluted share of $3.35
Result: reported results

Exact text from the filing

For the year ended December 31, 2022, the company reported a net loss of $89.1 million, or a net loss per diluted share of $3.35

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Vera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-010114

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.